CN116019801A - Amino acid composition for promoting secretion of endogenous growth hormone - Google Patents
Amino acid composition for promoting secretion of endogenous growth hormone Download PDFInfo
- Publication number
- CN116019801A CN116019801A CN202310064007.9A CN202310064007A CN116019801A CN 116019801 A CN116019801 A CN 116019801A CN 202310064007 A CN202310064007 A CN 202310064007A CN 116019801 A CN116019801 A CN 116019801A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- growth hormone
- ornithine
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 37
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 37
- 239000000122 growth hormone Substances 0.000 title claims abstract description 37
- 230000028327 secretion Effects 0.000 title claims abstract description 20
- 230000001737 promoting effect Effects 0.000 title claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 35
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims abstract description 20
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 20
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 20
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960003104 ornithine Drugs 0.000 claims abstract description 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 19
- 229960002648 alanylglutamine Drugs 0.000 claims abstract description 19
- 108010044940 alanylglutamine Proteins 0.000 claims abstract description 19
- 239000004475 Arginine Substances 0.000 claims abstract description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 18
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 18
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 18
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000004472 Lysine Substances 0.000 claims abstract description 13
- SLPUVFBNQHVEEU-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid;2-oxopentanedioic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CCC(=O)C(O)=O SLPUVFBNQHVEEU-WCCKRBBISA-N 0.000 claims abstract description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 12
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940075858 ornithine alpha-ketoglutarate Drugs 0.000 claims abstract description 12
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims abstract description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004473 Threonine Substances 0.000 claims abstract description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 11
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000310 isoleucine Drugs 0.000 claims abstract description 11
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930182817 methionine Natural products 0.000 claims abstract description 11
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940043131 pyroglutamate Drugs 0.000 claims abstract description 11
- 239000004474 valine Substances 0.000 claims abstract description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 6
- 239000004471 Glycine Substances 0.000 claims abstract description 5
- 229940000635 beta-alanine Drugs 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 27
- 235000013402 health food Nutrition 0.000 claims description 25
- 206010013883 Dwarfism Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229960003121 arginine Drugs 0.000 abstract description 14
- 229960004441 tyrosine Drugs 0.000 abstract description 14
- 229960003646 lysine Drugs 0.000 abstract description 10
- 229960003136 leucine Drugs 0.000 abstract description 9
- 229960004452 methionine Drugs 0.000 abstract description 8
- 229960005190 phenylalanine Drugs 0.000 abstract description 8
- 229960002898 threonine Drugs 0.000 abstract description 8
- 229960004295 valine Drugs 0.000 abstract description 8
- 230000007774 longterm Effects 0.000 abstract description 6
- 229940024606 amino acid Drugs 0.000 abstract description 3
- 229960002743 glutamine Drugs 0.000 abstract description 3
- 229960002449 glycine Drugs 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 16
- 235000009697 arginine Nutrition 0.000 description 13
- 235000013305 food Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MJGBOFOZSAEULI-RUCXOUQFSA-N (2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H]1CCC(=O)N1 MJGBOFOZSAEULI-RUCXOUQFSA-N 0.000 description 1
- IEDIKTABXQYWBL-UHFFFAOYSA-N 3-aminopropanoic acid Chemical compound NCCC(O)=O.NCCC(O)=O IEDIKTABXQYWBL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000013433 optimization analysis Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention provides an amino acid composition for promoting secretion of endogenous growth hormone, the composition comprising: tyrosine, arginine, ornithine, lysine, glutamine, glycine, isoleucine, leucine, valine, threonine, methionine, phenylalanine, ornithine alpha-ketoglutarate, alanylglutamine, beta-alanine and pyroglutamate. The composition of the invention can effectively promote the secretion of endogenous growth hormone and promote the level of endogenous growth hormone. In addition, the medicine is convenient to take, has good compliance and is helpful for ensuring long-term efficacy.
Description
Technical Field
The present invention relates to the field of biology. In particular, the present invention relates to amino acid compositions for promoting secretion of endogenous growth hormone.
Background
Growth hormone (Human Growth Hormone, hGH) is a peptide hormone secreted by the anterior pituitary gland of the human body, and can promote bone, viscera and whole body growth, promote protein synthesis, influence fat and mineral metabolism, and play a key role in the growth and development of the human body. At present, the limited schemes for effectively improving the growth hormone level in human bodies mainly surround exogenous supplementation through a plurality of recombinant human growth hormone injections. Although the method can effectively and rapidly raise the growth hormone level, the method has the problems of extremely high price, difficult compliance of users due to the need of periodic injection, frequent needle leakage and the like, and further difficult guarantee of long-term efficacy. At present, the promotion of endogenous growth hormone secretion by oral administration to raise the level of growth hormone has been a leading-edge hotspot developed in the field, but no effective technology has yet emerged.
Disclosure of Invention
The present invention aims to solve, at least to some extent, the technical problems existing in the prior art. Therefore, the invention provides the composition, and the medicine, the health food, the special medical formula food, the feed and the application containing the composition, and the composition can effectively promote the secretion of endogenous growth hormone and promote the level of the endogenous growth hormone. In addition, the medicine is convenient to take, has good compliance and is helpful for ensuring long-term efficacy.
In one aspect of the invention, the invention provides a composition. According to an embodiment of the invention, the composition comprises: tyrosine, arginine, ornithine, lysine, glutamine, glycine, isoleucine, leucine, valine, threonine, methionine, phenylalanine, ornithine alpha-ketoglutarate, alanylglutamine, beta-alanine and pyroglutamate. Thus, the composition according to the embodiment of the invention can effectively promote the secretion of endogenous growth hormone and promote the level of endogenous growth hormone.
According to an embodiment of the present invention, the above composition may further have at least one of the following additional technical features:
according to an embodiment of the invention, the weight ratio of tyrosine to ornithine is (1-2): (1-2); the weight ratio of alanyl glutamine to arginine is (1-2): (1-2).
According to an embodiment of the invention, the composition comprises: 8-12 parts by weight of tyrosine; 8-12 parts by weight of arginine; 8-12 parts by weight of ornithine; 5-7 parts by weight of lysine; 5-7 parts by weight of glutamine; 5-7 parts by weight of glycine; 5-7 parts by weight of isoleucine; 5-7 parts by weight of leucine; 5-7 parts by weight of valine; 5-7 parts by weight of threonine; 5-7 parts by weight of methionine; 5-7 parts by weight of phenylalanine; 5-7 parts by weight of ornithine alpha-ketoglutarate; 8-12 parts by weight of alanylglutamine; 5-7 parts by weight of beta-alanine; 5-7 parts by weight of pyroglutamate.
According to an embodiment of the invention, the composition comprises: 10 parts by weight of tyrosine; 10 parts by weight of arginine; 10 parts by weight of ornithine; 6.7 parts by weight of lysine; 6.7 parts by weight of glutamine; 6.7 parts by weight of glycine; 6.7 parts by weight of isoleucine; 6.7 parts by weight of leucine; 6.7 parts by weight of valine; 6.7 parts by weight of threonine; 6.7 parts by weight of methionine; 6.7 parts by weight of phenylalanine; 6.7 parts by weight of ornithine alpha-ketoglutarate; 10 parts by weight of alanylglutamine; 6.7 parts by weight of beta-alanine; 6.7 parts by weight of pyroglutamate.
In yet another aspect of the invention, the invention provides a medicament, health food, special medical use formula or feed. According to an embodiment of the invention, the medicament, health food, special medical use formula or feed comprises: the composition as described above. Therefore, the medicine, the health food, the formula food or the feed with special medical application according to the embodiment of the invention can effectively promote the secretion of endogenous growth hormone and promote the level of the growth hormone.
According to an embodiment of the present invention, the pharmaceutical, health food, special medical use formula or feed is in a form selected from the group consisting of a mixture, a tablet, a granule, a syrup, a capsule or an oral liquid.
In a further aspect of the invention, the invention proposes the use of the composition as described above for the preparation of a medicament, a health food, a formula for special medical use or a feed. According to an embodiment of the invention, the medicament, health food, special medical use formula or feed is for promoting endogenous growth hormone secretion.
According to an embodiment of the invention, the medicament is for preventing or treating diseases caused by endogenous growth hormone deficiency.
According to an embodiment of the invention, the disease is selected from dwarfism and/or osteoporosis.
According to an embodiment of the invention, the mode of administration of the medicament, health food, special medical use formula or feed is selected from oral administration.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Drawings
The foregoing and/or additional aspects and advantages of the invention will become apparent and may be better understood from the following description of embodiments taken in conjunction with the accompanying drawings in which:
FIG. 1 shows a graph of analysis of the levels of growth hormone in whole blood of mice after feeding the mice with the formulation of control group, experimental group 1;
FIG. 2 shows a graph of analysis of the whole blood growth hormone levels of mice after feeding mice with the control group, experimental group 2-4 formulas;
figure 3 shows a graph of the analysis of the whole blood growth hormone levels of mice after feeding mice with the control and experimental groups 5-7 formulations.
Detailed Description
Embodiments of the present invention are described in detail below. The following examples are illustrative only and are not to be construed as limiting the invention.
The present invention provides compositions and uses thereof, medicaments, health foods, special medical use formulas and feeds, each of which will be described in detail below.
Composition and method for producing the same
In one aspect of the invention, the invention provides a composition. According to an embodiment of the invention, the composition comprises: tyrosine, arginine, ornithine, lysine, glutamine, glycine, isoleucine, leucine, valine, threonine, methionine, phenylalanine, ornithine alpha-ketoglutarate, alanylglutamine, beta-alanine and pyroglutamate.
Through a great deal of experimental optimization analysis, the inventor of the invention discovers that Tyrosine (L-Tyrosine), arginine (L-Arginine), ornithine (L-orthonine), lysine (L-Lysine), glutamine (L-Glutamine), glycine (L-Glycine), isoleucine (L-Isoleucine), leucine (L-leucoine), valine (L-Valine), threonine (L-Threonine), methionine (L-Methionine), phenylalanine (L-Phenylalanine), ornithine Alpha-Ketoglutarate (Ornithine Alpha-Ketoglutate), alanyl Glutamine (L-Alany-L-Glutamine), beta-alanine (beta-alanine) and Pyroglutamate (L-Pyroglutamate) are compounded, so that the endogenous growth hormone secretion can be effectively promoted, and the endogenous growth hormone level can be improved. In addition, the composition can be applied in an oral form, so that the problem of poor compliance caused by a traditional injection mode is effectively solved, and long-term efficacy is ensured.
According to an embodiment of the invention, the weight ratio of tyrosine to ornithine is (1-2): (1-2); the weight ratio of alanyl glutamine to arginine is (1-2): (1-2). The inventor experiment finds that the tyrosine and ornithine and the alanyl glutamine and arginine have synergistic effect and jointly promote the secretion of endogenous growth hormone. Furthermore, the inventor obtains the better proportion through a large number of experiments, thereby better promoting the secretion of endogenous growth hormone.
According to an embodiment of the invention, a composition comprises: 8-12 parts by weight of tyrosine; 8-12 parts by weight of arginine; 8-12 parts by weight of ornithine; 5-7 parts by weight of lysine; 5-7 parts by weight of glutamine; 5-7 parts by weight of glycine; 5-7 parts by weight of isoleucine; 5-7 parts by weight of leucine; 5-7 parts by weight of valine; 5-7 parts by weight of threonine; 5-7 parts by weight of methionine; 5-7 parts by weight of phenylalanine; 5-7 parts by weight of ornithine alpha-ketoglutarate; 8-12 parts by weight of alanylglutamine; 5-7 parts by weight of beta-alanine; 5-7 parts by weight of pyroglutamate. The inventor obtains the better proportion through a large number of experiments, thereby further promoting the secretion of endogenous growth hormone. In a preferred embodiment, the composition comprises: 10 parts by weight of tyrosine; 10 parts by weight of arginine; 10 parts by weight of ornithine; 6.7 parts by weight of lysine; 6.7 parts by weight of glutamine; 6.7 parts by weight of glycine; 6.7 parts by weight of isoleucine; 6.7 parts by weight of leucine; 6.7 parts by weight of valine; 6.7 parts by weight of threonine; 6.7 parts by weight of methionine; 6.7 parts by weight of phenylalanine; 6.7 parts by weight of ornithine alpha-ketoglutarate; 10 parts by weight of alanylglutamine; 6.7 parts by weight of beta-alanine; 6.7 parts by weight of pyroglutamate.
Pharmaceutical, health food, special medical use formula food or feed
In yet another aspect of the invention, the invention provides a medicament, health food, special medical use formula or feed. According to an embodiment of the invention, the medicament, the health food, the special medical use formula or the feed comprises: the composition as described above. Thus, the medicine, the health food, the special medical formula food (also called as "special medical food") or the feed according to the embodiment of the invention can effectively promote the secretion of endogenous growth hormone and promote the level of endogenous growth hormone.
According to an embodiment of the present invention, the dosage form of the medicament, the health food, the special medical use formula or the feed is selected from the group consisting of a mixture, a tablet, a granule, a syrup, a capsule or an oral liquid.
The pharmaceutical, health food, biomedical food or feed of the present invention may further include pharmaceutically, food or feed acceptable excipients, and specifically may include excipients, lubricants, preservatives, fillers, solubilizers, stabilizers, etc., for example, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gel, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc. For feeds, it may further comprise conventional additions of substances for ensuring normal growth metabolic requirements, such as ration.
The invention does not limit the intake mode of medicines, special medical foods, health foods or feeds strictly, and the health foods and feeds are only taken through the alimentary canal, such as oral administration; the special medical food can be taken orally or fed by a tube feeding way, so that the special medical food is convenient for people with limited feeding; the administration mode of the medicine can be peritoneal, vein, muscle, subcutaneous, cortex, oral, nasal, lung, rectum, etc. Wherein, the oral administration mode is preferably selected, the administration is convenient, the compliance is good, the problem of poor compliance caused by the traditional injection mode is effectively solved, and the long-term efficacy is ensured.
Use of the same
In a further aspect of the invention, the invention proposes the use of the composition as described above for the preparation of a medicament, a health food, a formula for special medical use or a feed. According to embodiments of the present invention, a medicament, health food, special medical use formula or feed is used to promote endogenous growth hormone secretion.
According to an embodiment of the invention, the mode of administration of the medicament, the health food, the special medical use formula or the feed is selected from oral administration. Therefore, the medicine is convenient to apply, has good compliance and is helpful for ensuring long-term efficacy.
According to embodiments of the present invention, the medicament is used for preventing or treating diseases caused by endogenous growth hormone deficiency. In some embodiments, the disease is selected from dwarfism and/or osteoporosis.
In the present invention, the term "treatment" is used to refer to obtaining a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing the disease or symptoms thereof, and/or may be therapeutic in terms of partially or completely curing the disease and/or adverse effects caused by the disease. As used herein, "treating" encompasses diseases in mammals, particularly humans, including: (a) Preventing the occurrence of a disease or disorder in an individual susceptible to the disease but not yet diagnosed with the disease; (b) inhibiting disease, e.g., arresting disease progression; or (c) alleviating a disease, e.g., alleviating symptoms associated with a disease. As used herein, "treating" or "treatment" encompasses any administration of a drug or compound to an individual to treat, cure, alleviate, ameliorate, reduce or inhibit a disease in the individual, including, but not limited to, administration of a drug comprising a composition described herein to an individual in need thereof.
The frequency and dosage of administration of the medicament of the present invention may be determined by a number of relevant factors including the type of disease to be treated, the route of administration, the age, sex, weight and severity of the disease of the patient, and the type of medicament as an active ingredient. According to some embodiments of the invention, the daily dose may be divided into 1 dose, 2 doses or more in a suitable form to be administered 1, 2 or more times over the whole period of time, as long as a therapeutically effective amount is achieved.
The term "therapeutically effective amount" refers to an amount of a drug sufficient to significantly ameliorate some of the symptoms associated with a disease or disorder, i.e., an amount that provides a therapeutic effect for a given disorder and dosing regimen. For example, in treatment, a drug that reduces, prevents, delays, inhibits or retards any symptom of a disease or disorder should be therapeutically effective. A therapeutically effective amount of the drug is not required to cure the disease or condition, but will provide treatment for the disease or condition such that the onset of the disease or condition is delayed, prevented or prevented, or symptoms of the disease or condition are alleviated, or the period of the disease or condition is altered, or for example the disease or condition becomes less severe, or recovery is accelerated in an individual.
The scheme of the present invention will be explained below with reference to examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
The C57BL/6J mice were fed doses formulated according to the following experimental groups and 2 microliters of whole blood was withdrawn through the tail vein at 20 days 15, 30, 45, 60 post-feeding, and the growth hormone levels of the mice were measured, as described in detail in literature stepn, f.j., huang, l., ngo, s.t., leong, j.w., tan, h.y., xie, t.y., parlow, a.f., velhuis, j.d., waters, m.j., & Chen, c. (2011) Development of a method for the determination of pulsatile growth hormone secretion in mice.endocrinology,152 (8), 3165-3171.Https:// doi.org/10.1210/en.2011-0253.
Experiment group 1:10mg/kg tyrosine; arginine at 10 mg/kg; 10mg/kg ornithine; 6.7mg/kg lysine; 6.7mg/kg glutamine; 6.7mg/kg glycine; 6.7mg/kg of isoleucine; 6.7mg/kg leucine; valine at 6.7 mg/kg; 6.7mg/kg threonine; methionine at 6.7 mg/kg; 6.7mg/kg phenylalanine; 6.7mg/kg ornithine alpha ketoglutarate; 10mg/kg alanylglutamine; beta alanine at 6.7 mg/kg; 6.7mg/kg of pyroglutamate, based on the weight of the mice.
Experiment group 2:60mg/kg tyrosine, calculated on the weight of the mice.
Experiment group 3:60mg/kg ornithine, calculated on the weight of the mice.
Experiment group 4:30mg/kg tyrosine, 30mg/kg ornithine, calculated on the weight of the mice.
Experimental group 5:60mg/kg alanylglutamine, based on the weight of the mice.
Experiment group 6:60mg/kg arginine, calculated on the weight of the mice.
Experiment group 7:30mg/kg alanylglutamine, 30mg/kg arginine, based on the weight of the mice.
Control group: no addition was made.
As shown in fig. 1, it can be seen that the whole blood growth hormone level of mice was highest after administration of the composition of the formulation of experimental group 1, compared to the control group, indicating that the formulation can effectively promote growth hormone secretion and increase growth hormone level.
As shown in fig. 2 and 3, there is a synergistic effect between tyrosine and ornithine and alanylglutamine and arginine, which together promote endogenous growth hormone secretion.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (10)
1. A composition, wherein the composition comprises: tyrosine, arginine, ornithine, lysine, glutamine, glycine, isoleucine, leucine, valine, threonine, methionine, phenylalanine, ornithine alpha-ketoglutarate, alanylglutamine, beta-alanine and pyroglutamate.
2. The composition according to claim 1, wherein the weight ratio of tyrosine to ornithine is (1-2): (1-2);
the weight ratio of alanyl glutamine to arginine is (1-2): (1-2).
3. The composition of claim 1, wherein the composition comprises:
8-12 parts by weight of tyrosine;
8-12 parts by weight of arginine;
8-12 parts by weight of ornithine;
5-7 parts by weight of lysine;
5-7 parts by weight of glutamine;
5-7 parts by weight of glycine;
5-7 parts by weight of isoleucine;
5-7 parts by weight of leucine;
5-7 parts by weight of valine;
5-7 parts by weight of threonine;
5-7 parts by weight of methionine;
5-7 parts by weight of phenylalanine;
5-7 parts by weight of ornithine alpha-ketoglutarate;
8-12 parts by weight of alanylglutamine;
5-7 parts by weight of beta-alanine;
5-7 parts by weight of pyroglutamate.
4. The composition of claim 1, wherein the composition comprises:
10 parts by weight of tyrosine;
10 parts by weight of arginine;
10 parts by weight of ornithine;
6.7 parts by weight of lysine;
6.7 parts by weight of glutamine;
6.7 parts by weight of glycine;
6.7 parts by weight of isoleucine;
6.7 parts by weight of leucine;
6.7 parts by weight of valine;
6.7 parts by weight of threonine;
6.7 parts by weight of methionine;
6.7 parts by weight of phenylalanine;
6.7 parts by weight of ornithine alpha-ketoglutarate;
10 parts by weight of alanylglutamine;
6.7 parts by weight of beta-alanine;
6.7 parts by weight of pyroglutamate.
5. A medicament, health food, special medical use formula or feed, comprising: the composition of any one of claims 1 to 4.
6. The medicament, health food, special medical use formula or feed according to claim 5, wherein the dosage form of the medicament, health food, special medical use formula or feed is selected from the group consisting of mixture, tablet, granule, syrup, capsule or oral liquid.
7. Use of a composition according to any one of claims 1 to 4 for the preparation of a medicament, a health food, a special medical use formula or a feed, characterized in that the medicament, health food, special medical use formula or feed is used for promoting endogenous growth hormone secretion.
8. The use according to claim 7, wherein the medicament is for the prevention or treatment of diseases caused by a deficiency of endogenous growth hormone.
9. The use according to claim 8, wherein the disease is selected from dwarfism and/or osteoporosis.
10. The use according to claim 7, wherein the pharmaceutical, nutraceutical, special medical use formula or feed is administered orally.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310064007.9A CN116019801B (en) | 2023-01-13 | 2023-01-13 | Amino acid composition for promoting secretion of endogenous growth hormone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310064007.9A CN116019801B (en) | 2023-01-13 | 2023-01-13 | Amino acid composition for promoting secretion of endogenous growth hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116019801A true CN116019801A (en) | 2023-04-28 |
| CN116019801B CN116019801B (en) | 2024-04-05 |
Family
ID=86075726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310064007.9A Active CN116019801B (en) | 2023-01-13 | 2023-01-13 | Amino acid composition for promoting secretion of endogenous growth hormone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116019801B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346264B1 (en) * | 1999-04-27 | 2002-02-12 | International Health Products And Services Ltd. | Supplement for restoring growth hormone levels |
| KR20020061379A (en) * | 2001-01-16 | 2002-07-24 | 주식회사 바이오소프트텍 | Composition for Stimulating Secretion of Growth Hormone |
| CN1557292A (en) * | 2004-01-15 | 2004-12-29 | 高春平 | Formulation for improving human growth hormone release and its uses |
| US20210379001A1 (en) * | 2020-06-05 | 2021-12-09 | 1198966 B.C. Ltd. | Supplement including gamma-aminobutyric acid for restoring growth hormone levels |
-
2023
- 2023-01-13 CN CN202310064007.9A patent/CN116019801B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346264B1 (en) * | 1999-04-27 | 2002-02-12 | International Health Products And Services Ltd. | Supplement for restoring growth hormone levels |
| KR20020061379A (en) * | 2001-01-16 | 2002-07-24 | 주식회사 바이오소프트텍 | Composition for Stimulating Secretion of Growth Hormone |
| CN1557292A (en) * | 2004-01-15 | 2004-12-29 | 高春平 | Formulation for improving human growth hormone release and its uses |
| US20210379001A1 (en) * | 2020-06-05 | 2021-12-09 | 1198966 B.C. Ltd. | Supplement including gamma-aminobutyric acid for restoring growth hormone levels |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116019801B (en) | 2024-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5042312B2 (en) | Pharmaceutical composition for oral delivery comprising HGH | |
| JP7330471B2 (en) | Use of CHP (cyclo-hyspro) for prevention, amelioration or treatment of fibrosis | |
| US20190367574A1 (en) | Method of treating nash using a long-acting mutant human fibroblast growth factor | |
| KR20110033122A (en) | Orally administrable dosage forms comprising angiogenin and uses thereof | |
| US20080095837A1 (en) | Human growth hormone formulations | |
| WO2020175817A1 (en) | Composition for preventing, ameliorating, or treating fibrosis | |
| CN116019801B (en) | Amino acid composition for promoting secretion of endogenous growth hormone | |
| CN107137417B (en) | Pharmaceutical composition for treating cachexia and application thereof | |
| WO2012105477A1 (en) | Analgesic | |
| EP4331583A1 (en) | Blood carnitine-increasing agent | |
| CN113956334B (en) | Application of brown adipocyte secretory peptide and derivative thereof in prevention and treatment of obesity | |
| EA010353B1 (en) | Association of rosiglitazone or a salt thereof and coenzyme q, use thereof and pharmaceutical compositions comprising said association | |
| KR20200053069A (en) | Pharmaceutical composition for preventing or treating obesity comprising cyclo-hispro | |
| WO2021089554A1 (en) | Intranasal administration of merotocin for improving lactation | |
| US20160114002A1 (en) | Compositions comprising plant proteins and methods for prevention of metabolic and cardiovascular pathologies in patient with cardiometabolic risk, including hyperglycemia | |
| WO2016031264A1 (en) | Skeletal muscle bulking agent and use thereof | |
| KR102246627B1 (en) | A composition comprising hmba for preventing and treating obesity | |
| WO2021024855A1 (en) | Therapeutic agent or prophylactic agent for fibromyalgia | |
| CN111212637A (en) | Use of benzoate-containing compositions for treating glycine encephalopathy | |
| WO2021106760A1 (en) | Composition for preventing decrease in muscle mass, preventing weakness of muscular power, increasing muscle mass or strengthening muscular power | |
| CN117138026A (en) | Animal extract composition for promoting endogenous growth hormone secretion | |
| US20240115530A1 (en) | Administration of baiba to increase benefit of losing weight of intermittent fasting | |
| US11819508B2 (en) | Miltefosine for the treatment of viral infections including covid-19 | |
| WO2022004788A1 (en) | Ameliorating agent or prophylactic agent for muscle weakness symptom in disease or syndrome associated with metabolic disorder | |
| CN1452482A (en) | Synergistic compositions contg. choline base and cuccinic acid for insulin resistance and diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |